Compare Cassava Sciences Inc (FLNA) vs iShares China Large-Cap ETF (FXI) Price & Performance

Filana Therapeutics (FLNA) trades at $0.82, down 6.77% today, amid bearish technical signals but with positive fundamental catalysts. The company shows improving quarterly EPS beats and a favorable EV/EBITDA of 1.03, though it remains unprofitable with negative cash flow. Recent FDA clearance for its epilepsy drug trial has generated optimism, reflected in strong analyst buy ratings (67% consensus).

The outlook balances clinical progress against financial strain. The FDA hold lift on simufilam provides a clear near-term catalyst for Phase 2a trials starting in 2027, supporting the bullish analyst view. However, high cash burn (-$33M net CF in 2025) and lack of revenue pose significant risks to sustainability, requiring careful monitoring of funding and trial milestones.

FXI, the iShares China Large-Cap ETF, trades at $33.42, down 1.04% with bearish technical signals from moving averages. The ETF faces headwinds from China's economic challenges and trade tensions, though it trades at a significant discount to U.S. equities with a P/E of 11.10 versus the S&P 500's 22.54. Recent geopolitical developments from the Trump-Xi summit and China's export dynamics create mixed sentiment.

The outlook remains cautious with technical indicators signaling selling pressure, while fundamental valuation appears attractive for risk-tolerant investors seeking China exposure. Key risks include ongoing U.S.-China tensions, China's industrial overcapacity, and weak domestic consumption that could limit upside potential despite the valuation discount.